The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination

Am J Obstet Gynecol. 2007 Oct;197(4):337-9. doi: 10.1016/j.ajog.2007.08.030.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Cost-Benefit Analysis
  • Female
  • Guidelines as Topic
  • Humans
  • Mass Screening / economics
  • Mass Screening / methods
  • Papillomaviridae / growth & development*
  • Papillomavirus Infections / complications
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / administration & dosage*
  • Papillomavirus Vaccines / economics
  • Uterine Cervical Dysplasia / diagnosis
  • Uterine Cervical Dysplasia / economics
  • Uterine Cervical Dysplasia / prevention & control*
  • Uterine Cervical Dysplasia / virology
  • Uterine Cervical Neoplasms / diagnosis
  • Uterine Cervical Neoplasms / economics
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology

Substances

  • Papillomavirus Vaccines